Abstract: The present invention relates to a composition comprising natural and synthetic actives. In particular, the present invention relates to a cosmetic composition comprising oleanolic acid and L-histidine. The cosmetic composition as disclosed herein is useful for preventing and reducing signs of skin aging.
CLIAMS:1. A cosmetic composition for preventing and reducing signs of skin aging comprising:
a) 0.00005% to 1% (w/w) of oleanolic acid;
b) 0.030% to 2.5% (w/w) of L-histidine; and
c) 70% to 99.9% (w/w) of a cosmetically acceptable carrier.
2. The cosmetic composition as claimed in claim 1, wherein the signs of skin aging are selected from the group consisting of wrinkles, fine lines, sagging skin, lack of radiance, and combinations thereof.
3. The cosmetic composition as claimed in claim 1, wherein the cosmetic composition comprises 0.0001% (w/w) of oleanolic acid.
4. The cosmetic composition as claimed in claim 1, wherein the cosmetic composition comprises 0.039% (w/w) of L- histidine.
5. The cosmetic composition as claimed in claim 1, wherein the cosmetic composition is formulated in a form selected from the group consisting of skin creams, skin lotions, sunscreen lotions, anti-aging products, skin foundations, gels, skin spot correction products, serums, moisturizing sprays, facial scrubs, and facial peels.
6. A method for preventing and reducing signs of skin aging by topically administering a cosmetic composition, wherein the cosmetic composition comprises:
a) 0.00005% to 1% (w/w) of oleanolic acid;
b) 0.030% to 2.5% (w/w) of L-histidine; and
c) 0% to 99.9% (w/w) of a cosmetically acceptable carrier.
7. The method as claimed in claim 6, wherein the signs of skin aging are selected from the group consisting of wrinkles, fine lines, sagging skin, lack of radiance, and combinations thereof.
8. The method as claimed in claim 6, wherein the cosmetic composition comprises 0.0001% (w/w) of oleanolic acid.
9. The method as claimed in claim 6, wherein the cosmetic composition comprises 0.039% (w/w) of L-histidine. ,TagSPECI:As Attached
| # | Name | Date |
|---|---|---|
| 1 | 1984-CHE-2013-FER.pdf | 2019-11-27 |
| 1 | spec.pdf | 2013-05-03 |
| 2 | Form 18 [12-01-2017(online)].pdf | 2017-01-12 |
| 2 | Sequence Listing_PD009279IN-SC_ST25.txt | 2013-05-03 |
| 3 | FORM 5.pdf | 2013-05-03 |
| 3 | 1984-CHE-2013 CORRESPONDENCE OTHERS 20-06-2013.pdf | 2013-06-20 |
| 4 | FORM 3.pdf | 2013-05-03 |
| 4 | 1984-CHE-2013 FORM-1 20-06-2013.pdf | 2013-06-20 |
| 5 | 1984-CHE-2013 POWER OF ATTORNEY 20-06-2013.pdf | 2013-06-20 |
| 5 | fig.pdf | 2013-05-03 |
| 6 | 1984-CHE-2013 CORRESPONDENCE OTHERS 13-05-2013.pdf | 2013-05-13 |
| 7 | 1984-CHE-2013 POWER OF ATTORNEY 20-06-2013.pdf | 2013-06-20 |
| 7 | fig.pdf | 2013-05-03 |
| 8 | 1984-CHE-2013 FORM-1 20-06-2013.pdf | 2013-06-20 |
| 8 | FORM 3.pdf | 2013-05-03 |
| 9 | 1984-CHE-2013 CORRESPONDENCE OTHERS 20-06-2013.pdf | 2013-06-20 |
| 9 | FORM 5.pdf | 2013-05-03 |
| 10 | Sequence Listing_PD009279IN-SC_ST25.txt | 2013-05-03 |
| 10 | Form 18 [12-01-2017(online)].pdf | 2017-01-12 |
| 11 | spec.pdf | 2013-05-03 |
| 11 | 1984-CHE-2013-FER.pdf | 2019-11-27 |
| 1 | searchstrategy_08-11-2019.pdf |